Skip to content
The Policy VaultThe Policy Vault

Imbruvica (ibrutinib) — Highmark

Chronic Graft vs. Host Disease (cGVHD)

Initial criteria

  • age ≥ 1 year
  • diagnosis of cGVHD (ICD-10 D89.811)
  • received prior systemic therapy
  • if oral suspension requested: inability to swallow plan-preferred oral tablets or oral capsules